PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.
about
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewSafety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trialPIK3CA expression in diffuse large B cell lymphoma tissue and the effect of its knockdown in vitro.Team work matters: dual inhibition puts non-hodgkin lymphoma under siege.Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells.Establishment and characterization of a novel MYC/BCL2 "double-hit" diffuse large B cell lymphoma cell line, RCCo-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma.A three-signal model of T-cell lymphoma pathogenesisTargeting mTOR for the treatment of B cell malignancies.Mcl-1 as a potential therapeutic target for human hepatocelluar carcinoma.Targeting protein kinase C in mantle cell lymphoma.Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma.Dual inhibition of histone deacetylases and phosphoinositide 3-kinases: effects on Burkitt lymphoma cell growth and migration.Survival control of malignant lymphocytes by anti-apoptotic MCL-1.The role of VDR and BIM in potentiation of cytarabine-induced cell death in human AML blasts.VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of Bim.CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial.Panobinostat sensitizes KRAS-mutant non-small-cell lung cancer to gefitinib by targeting TAZ.Multifaceted Roles of GSK-3 in Cancer and Autophagy-Related Diseases.Pharmacotherapeutic Management of Pediatric Lymphoma.Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway.Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma.Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma.
P2860
Q27304386-1B1101B1-49F0-469C-8B1A-CF3738F8A4B4Q33431267-1D32CB46-5091-47A4-8824-B5A9B8CBABB3Q33602560-EE94860A-4DD5-478F-9E97-81D6884888F6Q35610195-485A444E-8B4A-45E2-8B6E-E6DB0E75F03BQ35856126-68BAC8EE-CE19-491A-B229-5D6D3F0475F3Q36232304-A63B6A13-7C2E-4BE0-80D7-78B5C63667BBQ36337587-32A3BD2A-D792-455D-909C-558A318C2AC3Q36725307-2AEEFFC4-B2AB-4061-827B-125910960D3DQ37706739-E535F06C-8B79-445D-B5DF-F9F28368FA5AQ38593164-8216D3E2-AB49-416A-B5BC-00CF89BE55D4Q38709825-2CEAEC81-9D90-4FFF-9A31-CB7A6CAC76ACQ38755343-B359B721-560C-427D-B5D6-5DD0029A7BB8Q38791124-FCC68144-D3C5-42D2-93E4-A13891D674CEQ38798340-2BACF52E-2FF0-4DAC-9C87-FEE73B5EAC81Q38819975-7F1184BA-75D7-4ABE-B87D-8687BDE4630AQ38914858-E6AA2684-C71B-4257-84E3-61A7826AE3D2Q39796064-2F51389D-6357-44A8-AC6B-7CD80B01FB0CQ47107700-AE081C07-88EA-4A61-B1E1-BEEC25AFC755Q47109026-696059C9-3372-40EB-865D-469AF59EBF07Q48121325-247AF392-331C-4A17-8AC0-903E4C7E149BQ48146413-FE25A690-AB8C-4423-8448-198E5752D782Q48321203-CDBAE100-F945-48CE-A5A9-BBAAF6850C6DQ49359645-A25FA9A7-0946-4B61-84B0-1DA8DE9D35B7Q50102285-FA7624C1-7869-4565-983C-F74AD986DE27Q55010628-ECEE12F5-3537-45C1-952F-EDD3E1E74929
P2860
PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
PI3K/mTOR inhibition markedly ...... chanisms in vitro and in vivo.
@ast
PI3K/mTOR inhibition markedly ...... chanisms in vitro and in vivo.
@en
PI3K/mTOR inhibition markedly ...... chanisms in vitro and in vivo.
@nl
type
label
PI3K/mTOR inhibition markedly ...... chanisms in vitro and in vivo.
@ast
PI3K/mTOR inhibition markedly ...... chanisms in vitro and in vivo.
@en
PI3K/mTOR inhibition markedly ...... chanisms in vitro and in vivo.
@nl
prefLabel
PI3K/mTOR inhibition markedly ...... chanisms in vitro and in vivo.
@ast
PI3K/mTOR inhibition markedly ...... chanisms in vitro and in vivo.
@en
PI3K/mTOR inhibition markedly ...... chanisms in vitro and in vivo.
@nl
P2093
P2860
P1476
PI3K/mTOR inhibition markedly ...... chanisms in vitro and in vivo.
@en
P2093
Elisa C Benson
Jonathan Friedberg
LaShanale Wallace
Mandy Mayo Aust
Steven Grant
P2860
P304
P356
10.1158/1078-0432.CCR-14-0034
P407
P577
2014-07-28T00:00:00Z